Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

The Lancet

Volumn 389, Issue 10088, 2017, Pages 2492-2502

  El Khoueiry, Anthony B ^a   Sangro, Bruno ^b   Yau, Thomas ^c   Crocenzi, Todd S ^d   Kudo, Masatoshi ^e   Hsu, Chiun ^f   Kim, Tae You ^g   Choo, Su Pin ^h   Trojan, Jörg ⁱ   Welling, Theodore H ^j   Meyer, Tim ^k   Kang, Yoon Koo ^l   Yeo, Winnie ^m   Chopra, Akhil ⁿ   Anderson, Jeffrey ^o   dela Cruz, Christine ^o   Lang, Lixin ^o   Neely, Jaclyn ^o   Tang, Hao ^o   Dastani, Homa B ^o   Melero, Ignacio ^p,q   more..

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d Providence Cancer Center   (United States)

^e KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g Seoul National University Hospital   (South Korea)

^h DIVISION OF MEDICAL ONCOLOGY   (Singapore)

ⁱ UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^j UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^k ROYAL FREE HOSPITAL   (United Kingdom)

^l University of Ulsan   (South Korea)

^m CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

ⁿ Johns Hopkins Singapore   (Singapore)

^o BRISTOL MYERS SQUIBB   (United States)

^p Instituto Carlos III   (Spain)

^q UNIVERSITY OF NAVARRA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; NIVOLUMAB; SORAFENIB; TRIACYLGLYCEROL LIPASE; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; TUMOR MARKER;

ADRENAL INSUFFICIENCY; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; ARTIFICIAL EMBOLIZATION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; DECREASED APPETITE; DIARRHEA; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYPOALBUMINEMIA; HYPONATREMIA; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER SURGERY; LOCAL THERAPY; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MEDICATION COMPLIANCE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RADIOEMBOLIZATION; RASH; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SIDE EFFECT; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VIRUS LOAD; XEROSTOMIA; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; LIVER TUMOR; METABOLISM; PATHOLOGY; TIME FACTOR; TREATMENT OUTCOME; TUMOR VOLUME;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; B7-H1 ANTIGEN; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 85018660134     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)31046-2     Document Type: Article

References (26)

1. Torre, LA, Bray, F, Siegel, RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 65 (2015), 87–108.
2. Llovet, JM, Zucman-Rossi, J, Pikarsky, E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers, 2, 2016, 16018.
3. McGlynn, KA, Petrick, JL, London, WT, Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis 19 (2015), 223–238.
4. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56 (2012), 908–943.
5. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Hepatobiliary Cancers. Version 1.2017. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp, 2017 (accessed April 3, 2017).
6. Llovet, JM, Ricci, S, Mazzaferro, V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008), 378–390.
7. Bruix, J, Qin, S, Merle, P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389 (2017), 56–66.
8. Whiteside, TL, Demaria, S, Rodriguez-Ruiz, ME, et al. Emerging opportunities and challenges in cancer immunotherapy. Clin Cancer Res 22 (2016), 1845–1855.
9. Weber, JS, D'Angelo, SP, Minor, D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16 (2015), 375–384.
10. Motzer, RJ, Escudier, B, McDermott, DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373 (2015), 1803–1813.
11. Topalian, SL, Drake, CG, Pardoll, DM, Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27 (2015), 450–461.
12. Prieto, J, Melero, I, Sangro, B, Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 12 (2015), 681–700.
13. + T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer 128 (2011), 887–896.
14. Flecken, T, Schmidt, N, Hild, S, et al. Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma. Hepatology 59 (2014), 1415–1426.
15. Breous, E, Thimme, R, Potential of immunotherapy for hepatocellular carcinoma. J Hepatol 54 (2011), 830–834.
16. Eisenhauer, EA, Therasse, P, Bogaerts, J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
17. EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 16 (1990), 199–208.
18. Topalian, SL, Hodi, FS, Brahmer, JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 (2012), 2443–2454.
19. Cheng, AL, Kang, YK, Chen, Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Oncol 10 (2009), 25–34.
20. Bruix, J, Raoul, JL, Sherman, M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 57 (2012), 821–829.
21. Cheng, AL, Guan, Z, Chen, Z, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III sorafenib Asia-Pacific trial. Eur J Cancer 48 (2012), 1452–1465.
22. Borghaei, H, Paz-Ares, L, Horn, L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 (2015), 1627–1639.
23. Brahmer, J, Reckamp, KL, Baas, P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373 (2015), 123–135.
24. Ansell, SM, Lesokhin, AM, Borrello, I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372 (2015), 311–319.
25. Ferris, RL, Blumenschein, G Jr, Fayette, J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 385 (2016), 1856–1867.
26. Sangro, B, Gomez-Martin, C, de la Mata, M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 59 (2013), 81–88.